Detalhe da pesquisa
1.
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.
Future Oncol
; 20(15): 959-968, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38390818
2.
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Blood
; 137(12): 1669-1678, 2021 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33067632
3.
Myofibroblast stroma differentiation in infiltrative basal cell carcinoma is accompanied by regulatory T-cells.
J Cutan Pathol
; 50(6): 544-551, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36562598
4.
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.
Br J Cancer
; 123(6): 885-897, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32713938
5.
PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations.
Eur J Nucl Med Mol Imaging
; 47(1): 51-60, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31410538
6.
Knowledge and Influence of Predatory Journals in Dermatology: A Pan-Austrian Survey.
Acta Derm Venereol
; 99(1): 58-62, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30206639
7.
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
Br J Cancer
; 119(6): 670-674, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30202085
8.
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 18(5): 611-622, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28359784
9.
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
Cancer Immunol Immunother
; 66(6): 683-695, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28238174
10.
Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in Large Arteries.
Circulation
; 142(24): 2396-2398, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32894978
11.
Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.
Cancer Immunol Immunother
; 65(9): 1015-34, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27372293
12.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 16(4): 375-84, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25795410
13.
Einfluss der Covid-19-Pandemie auf die dermatoonkologische Versorgung in Österreich.
J Dtsch Dermatol Ges
; 18(7): 778-779, 2020 Jul.
Artigo
em Alemão
| MEDLINE | ID: mdl-32713147
14.
DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma.
Target Oncol
; 19(2): 263-275, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38401029
15.
Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
Melanoma Res
; 34(2): 142-151, 2024 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38092013
16.
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
Eur J Cancer
; 199: 113561, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38278009
17.
Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy.
Clin Cancer Res
; 30(1): 159-175, 2024 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37861398
18.
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Nat Med
; 29(11): 2835-2843, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37845511
19.
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
J Clin Oncol
; 41(3): 528-540, 2023 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35998300
20.
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.
Eur J Cancer
; 193: 113252, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708630